In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Merck MRK reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...

Merck (NYSE:MRK) beat Street forecasts with its Q3 2024 revenue on Thursday as its blockbuster cancer therapy Keytruda continued to drive sales growth while its human papillomavirus vaccine ...

CNBC's Becky Quick reports on the company's quarterly earnings results. Kamala Harris Could Break 32-Year Record in Texas, Survey Suggests The IRS just made a ruling on 401(k) company matches that ...

The New York Stock Exchange (ICE) on Friday announced plans to extend its weekday trading on its U.S. equities market to 22 hours a day. That would mean the NYSE Arca — the top electronic ...

The stock is also trading below its 200- and 50-day moving averages. Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key top-line ...